Table 1. Main characteristics of studies exploring the relationship between p62 expression and tumor prognosis.
| Author | Year | Region | Cancer Type | No. of Patients | Follow-up Time Median (range) | Detection Method | Cut-off | Outcomes | NOS Score |
|---|---|---|---|---|---|---|---|---|---|
| Shun Nakayama [16] | 2017 | Japan | Colorectal Carcinoma | 118 | 69.8 m (2–131) | IHC (MBL) | ≥ 10% | OS | 7 |
| Akihito Arai [17] | 2017 | Japan | Hypopharyngeal Carcinoma | 54 | NR | IHC (MBL) | NR | DFS | 5 |
| Diana Y. L. Tang [18] | 2016 | UK | Melanoma | 75 | 5 y | IHC (NR) | ≥ 20% | OS, DFS | 6 |
| Xifeng Wang [19] | 2015 | China | Non-Small Cell Lung Cancer | 104 | 48.5 m (3–96.5) | IHC (Abcam) | IRS ≥ 4 | OS | 7 |
| Reiko Iwadate [20] | 2015 | Japan | Endometrial Cancer | 194 | 22.0 m (2.0–58.0) | IHC (Santa Cruz) | ≥ 10% | OS | 8 |
| Mingfei Zhao [21] | 2015 | China | Gliomas | 75 | 24 m (6–60) | IHC (Santa Cruz) | IRS ≥ 3 | OS, DFS | 6 |
| Xianhan Jiang [22] | 2015 | China | Prostate Cancer | 149 | 10 y | IHC (Santa Cruz) | IRS ≥ 4 | OS | 7 |
| J-L Liu [23] | 2014 | China | Oral Squamous Cell Carcinoma | 195 | 47.08 ± 32.37 m | IHC (Abcam) | IRS ≥ 4 | OS, DFS | 8 |
| Reiko Iwadate [24] | 2014 | Japan | Epithelial Ovarian Cancer | 266 | 59 m (1–120) | IHC (Santa Cruz) | ≥ 10% | OS | 8 |
| Robert A Ellis [25] | 2014 | UK | Melanoma | 121 | 7 y | IHC (NR) | ≥ 20% | DFS | 7 |
| Sang Kyum Kim [26] | 2013 | Korea | Phyllodes Tumor | 190 | NR | IHC (Abcam) | IRS ≥ 2 | OS, DFS | 7 |
| Rong-Zhen Luo [27] | 2013 | China | Breast Cancer | 163 | 112 m (15–145) | IHC (Santa Cruz) | IRS ≥ 2 | OS, DFS | 7 |
| Jae Myung Park [28] | 2012 | USA | Colon Carcinoma | 178 | 4 y | IHC (MBL) | ≥ 50% | OS | 7 |
| Junjeong Choi [29] | 2012 | Korea | Breast Cancer | 489 | 82.0 ± 36.5 m | IHC (Abcam) | IRS ≥ 2 | OS, DFS | 8 |
| Sewha Kim [30] | 2012 | Korea | Breast Cancer | 119 | 59.2 ± 27.9 m | IHC (Abcam) | IRS ≥ 2 | OS, DFS | 6 |
| Daisuke Inoue [31] | 2012 | Japan | Lung Adenocarcinoma | 109 | 1626 d (17–3366) | IHC (Santa Cruz) | ≥ 10% | OS | 6 |
| Phil Rolland [32] | 2007 | UK | Breast Cancer | 523 | 76 m | IHC (INC) | ≥ 5% | OS | 8 |
| L-Z Xu [33] | 2016 | China | Breast Cancer | 369 | NR | IHC (NR) | NR | OS, DFS | 8 |
| Ji-Ye Kim [34] | 2014 | Italy | Breast Cancer | 334 | NR | IHC (Abcam) | ≥ 30% | DFS | 7 |
| Anna M. Schläfli [35] | 2016 | Switzerland | Non-Small Cell Lung Cancer | 446 | NR | IHC (MBL) | ≥ 25% | OS, DFS | 7 |
NR: Not Reported; y: year; m: month; d: day; OS: Overall Survival; DFS: Disease-Free Survival; IRS: Immunoreactive Score.